Article in Molecular pain. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Junwei DuMallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
Leland C SudlowMallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
Margaret H JohnsonMallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
Kanishk SatishMallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
Abraham VillagomezPaul L. Foster School of Medicine, El Paso, TX, USA.
Hongzhen HuIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Mikhail Y BerezinMallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-2670-2487
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
AN IMAGING-BASED APPROACH TO UNDERSTAND AND PREDICT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHYR01CA208623 · NCI · WASHINGTON UNIVERSITY · PI BEREZIN, MIKHAIL Y. · 2017 to 2021
$2.2M
Mapping Neural Recovery: Visualizing Peripheral Nerve Regeneration and Brain Plasticity Post-Peripheral Nerve InjuryR01NS139461 · NINDS · WASHINGTON UNIVERSITY · PI Mikhail Y. Berezin · 2025 to 2026
$1.1M
Molecular and cellular imaging of bone biopsies using AI augmented deep UV Raman microscopyR21CA269099 · NCI · TEXAS ENGINEERING EXPERIMENT STATION · PI BEREZIN, MIKHAIL Y., YAKOVLEV, VLADISLAV V. · 2022 to 2024
$577k
In vivo Visualization of Delayed Wallerian Degeneration in Peripheral Nerve InjuryR21NS135646 · NINDS · WASHINGTON UNIVERSITY · PI BEREZIN, MIKHAIL Y. · 2024 to 2025
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and dose-limiting side effect of oxaliplatin treatment, yet its molecular mechanisms remain incompletely understood. Calcitonin gene-related peptide alpha (CGRPα, encoded by
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
CGRP expression and signaling sensitization in a mouse model of chronic oxaliplatin-induced peripheral neuropathy. · full record | OpenQuestion